https://twitter.com/That_Hawaii_Guy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As predicted: back to .0001x.0002...
Now, if you think a bloated cow like this (that is dead stinking and floating down the river) will get up and run, buy some shares down here...and wait for the miracle...or reverse split as the case may be...lol...
But seriously that is a tremendous OS...you'd need incredible news just to get it to copper...but from here 25 bags is only a half penny...do not risk money you can't afford to lose.
Have you get a stash of physical silver? Have you got 90 days of food? THEN play a stock like this...
PAOG Targets Spring Launch Of Hemp Cultivar Facility
October 13 2020 - 09:20AM
InvestorsHub NewsWire
https://ih.advfn.com/stock-market/USOTC/pao-pk-PAOG/stock-news/83448146/paog-targets-spring-launch-of-hemp-cultivar-facili
Sandusky, OH -- October 13, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today confirmed an agreement with Puration, Inc. (USOTC: PURA) to build a proprietary hemp cultivar development facility on PURA’s Farmersville, Texas branded site and announced an April 2021 target date for construction to be completed.
PAOG recently acquired a hemp cultivation business from PURA and is now expanding upon that business to develop a proprietary hemp cultivar in conjunction with the company’s overall pharmaceutical focus.
PAOG is developing a hemp derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD).
The COPD treatment, RespRx, is derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
PAOG’s Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments.
PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA’s year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment.
www.paogroupinc.com
www.purationinc.com
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Puration, Inc.
Brian Shibley,
(800) 861-1350
info@aciconglomerated.com
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
Somebody collecting low 20s...a few mil at a time...
So funny. When everything else red: SOAN green. when everything else green: SOAN red.
Never mind the 'rona. "Right to try" could make us wealthy just on COPD...
I had no idea how big of a problem COPD is...
Right up there with cancer and diabetes...
Trips would be awesome. Last time I bought trips I sold 40s...
PAOG Taps Canopy Growth And Altria Resource
https://ih.advfn.com/stock-market/USOTC/pao-pk-PAOG/stock-news/83397005/paog-taps-canopy-growth-and-altria-resource
October 05 2020 - 11:24AM
InvestorsHub NewsWire
Sandusky, OH -- October 5, 2020 -- InvestorsHub NewsWire -- PAO Group, Inc. (USOTC: PAOG) today confirmed engaging Saul Kaye the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).
Saul Kaye is a global influencer in the medical cannabis industry, a widely respected speaker on cannabis industry movements and has been engaged in the past by other notable cannabis industry participants including Alvit, Canopy Growth (CGC), Altria and many other global cannabis companies.
Saul is a licensed pharmacist and a serial entrepreneur with both retail and e-commerce experience. He has founded multiple companies spanning six countries across the US, Europe, Israel and Australia.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
With RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.
The expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research. Two studies in particular, both of which highlight the research behind GW Pharmaceuticals’ cannabinoid treatments, shed light on PAOG’s wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.
One of the two studies is focused on CBD and the other on THC. The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells. The THC report seems to validate its ability to relieve pain, but it also indicates immune response manipulation capabilities to include anti-inflammatory reactions and the stimulation of immune responses to fight bad cells.
CBD Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/
THC Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219460/
In summary, existing publicly available cannabis treatment research further supports the research findings behind RespRx, and at the same time, the publicly available research sheds light on the expanded potential of PAOG’s RespRx overall technology.
The growing body of cannabis research is building convincing evidence behind how specific cannabinoids can beneficially impact specific immune responses. The research behind RespRx demonstrates how the process to derive RespRx can be manipulated to target specific cannabinoid extractions. Accordingly, as advancing cannabis research unveils further evidence behind how specific cannabinoids beneficially impact specific immune responses, PAOG is optimistic that it can utilize its overall cannabis extraction process to effectively derive formals with high concentrations of target cannabinoids. Hence, PAOG sees a more broad future of developing cannabis treatments beyond COPD.
In conjunction with PAOG’s acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. (USOTC: PURA) to develop a proprietary cultivar to support PAOG’s cannabis pharmaceutical treatment objectives.
PAOG has announced plans with PURA to expand upon PAOG’s hemp cultivation business to develop a proprietary hemp cultivar. PAOG and PURA are partnering on PURA’s Farmersville Brands initiative.
PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments.
PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA's year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment.
www.paogroupinc.com
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
And another 8%....probably should have bought those 20's...lol...
Nonsense there was big news in there but it was presented like it was nothing...
Host: "That's ground breaking!"
DiPrima Mumbles: "Yeah..."
13 million out...? This is a no brainer...
Holy Guacamole.
Well, if they can deliver on revs this thing has a chance now...as I said before billions was too much. Really easy for MMs to cheat when you got that many shares out. This OS will be easier to hold to account...among other things.
Plus they have brought products to market and taken a market share in a nich because they have good products...Uncle Warren told invest in companies whose products I use and understand. *OTC so speculate not invest; but these guys could go a long way if they'd just get their marketing together which it looks like they have...
Once I accidentally caught a dead fish.
It had more enthusiasm than Jim DiPrima...
What was the R/S ratio?
Ok, showing remarkable strength considering it just R/S'ed.
Higher highs and higher lows...
A long time ago in a land far far away I was a moderator on this board...LOL...too much cold sideways action made get bored and go elsewhere but I think it's time to start paying attention.
I have used their products in the past...and they have entered a nich and done well with Keto products...so...
Ok, only 19%...
Technically this is still HOT SIDEWAYS ACTION.
Was pretty sure it would bounce off 20 but not so sure as to dump money in...lol...and certainly didn't think it would happen this fast...
Still need volume if it is going to rocket but solid news about solid developments should send this drifting higher.
I can't decide...LOL
Sell everything or buy more...too many green days in a row...
Or maybe just sit and watch some more...been a great week, tho.
Buy 20s sell 25s. EZ...
LOL!
Been watching this stock for years...this is new.
Sideways and up? Usually can't hold gains for more than three sessions in a row but here we are...
If I wasn't such a disciplined investor I'd be tempted to buy more...but my free shares are worth 2x what I paid for them and adding a cost basis now would be fool hardy especially when I see so many sure bets in the silver and gold sectors...they will not explode (or maybe they will) like this OTC but they are in slow and steady uptrends...whereas this thing is all over the place with wild moves up and down...I think that's the longest green candle I've seen since dot com boom days. Those are always good omens...don't know if it going to crawl up or explode up but the trend is up...
Volume is light and news isn't expected by me anytime soon...are you guys expecting news? They usually put out PR every couple months so I don't feel like we are due.
Something is up tho...
Who is this "we" of whom you speak?
People who got 19s and 20s can sell 38s and 40s for an easy double...looks like high 50's is the resistance...
Please, they were dumping up in the 40s and 50s not down here in the 20s...this is retail being shaken out: look at the volume...
Buy 20's sell 40s and 50s...
Not even half a million shares...?
Hope they take it to trips again...
This is so not done. Look at the volume they used to take it down....
Better be back by Monday or you might miss the hot sideways action.
It's so thin, it has to run around in the shower to get wet...
How thin is it?
LOL...nobody likes to admit that their casino is rigged.
Anybody care to explain why this got halted other than to stop a run while the MMs got caught with their shorts down?
Certainly was effective for drying up the volume.
PAOG Expands Cannabis Pharma Treatment Research
Newsfile Corp.
Thu, September 24, 2020, 6:10 AM HST
https://finance.yahoo.com/news/paog-expands-cannabis-pharma-treatment-161000409.html
This wasn't exactly a fluff PR, it was actually pretty good news...too bad it's the OTC where buy the rumor sell the news is the norm. Also PAOG has a shitty track record when it comes to follow through...but they know how to sell shares.
Sandusky, Ohio--(Newsfile Corp. - September 24, 2020) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated affecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
With RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.
The expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research. Two studies in particular, both of which highlight the research behind GW Pharmaceuticals' cannabinoid treatments, shed light on PAOG's wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.
One of the two studies is focused on CBD and the other on THC. The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells. The THC report seems to validate its ability to relieve pain, but it also indicates immune response manipulation capabilities to include anti-inflammatory reactions and the stimulation of immune responses to fight bad cells.
CBD Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/
THC Research - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219460/
In summary, existing publicly available cannabis treatment research further supports the research findings behind RespRx, and at the same time, the publicly available research sheds light on the expanded potential of PAOG's RespRx overall technology.
The growing body of cannabis research is building convincing evidence behind how specific cannabinoids can beneficially impact specific immune responses. The research behind RespRx demonstrates how the process to derive RespRx can be manipulated to target specific cannabinoid extractions. Accordingly, as advancing cannabis research unveils further evidence behind how specific cannabinoids beneficially impact specific immune responses, PAOG is optimistic that it can utilize its overall cannabis extraction process to effectively derive formals with high concentrations of target cannabinoids. Hence, PAOG sees a more broad future of developing cannabis treatments beyond COPD.
In conjunction with PAOG's acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) to develop a proprietary cultivar to support PAOG's cannabis pharmaceutical treatment objectives.
Last week, PAOG announced plans with PURA to expand upon PAOG's hemp cultivation business to develop a proprietary hemp cultivar. PAOG and PURA are partnering on PURA's Farmersville Brands initiative.
PAOG's Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments.
PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA's year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment.
www.paogroupinc.com
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Puration, Inc.
Brian Shibley,
(800) 861-1350
info@aciconglomerated.com
Basically made it all back in a day...
How many bags from trips?
SILVER! We are being given gifts!
IVPAI -10%
FSM -13%
TGB -17% (Copper.)
WRN -17%
VGZ -12%
EXK -12%
SSRM -10%
AUY -9%
PAOG -6%
SOAN +3.45%
EWLL +73%
LOL
LOL in a sea of red SOAN is just a little green...
Good interview...